43 results about "Rectal Suppository" patented technology

Hypertonic sugar compositions administered by other than ingestion and swallowing or intravascular injection, such as by intranasal spray or drops, intraocular drops or ointment, oral spray, intraotic spray or drops, lozenges, chewable tablet, chewing gum, or gargle, pulmonary inhalation, vaginal or rectal suppositories, or transdermal creams, ointments, lotions, or patches, are effective to open the blood-brain barrier to permit entry into the central nervous system of a co-administered chemical compound, such as a nutrient or a therapeutic or diagnostic agent. In this way, the compositions and methods of the invention increase the therapeutic or diagnostic efficacy of such chemical compounds.

The endometriosis treatment protocol provides for administering to a female patient in need of treatment for endometriosis a pharmaceutical composition in a form suitable for vaginal or rectal delivery having a pharmaceutically effective amount of an aromatase inhibitor, which may be either a steroid or non-steroidal. The pharmaceutical composition may be formed as a vaginal suppository, a rectal suppository, a vaginal gel, a rectal gel, a vaginal cream or a rectal cream. The pharmaceutical composition may optionally have pharmaceutically effective amounts of progesterone and calcitriol, and may be administered in combination with an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition comprises an aromatase inhibitor administered vaginally or rectally and is administered in combination with oral calcitriol and the oral COX-2 inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.

This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses compositions, methodologies, and delivery mode for the utilization of probiotic organisms in therapeutic compositions for treatment and relief from the symptoms of urogenital infections by maintaining and restoring normal flora in humans. The composition includes one or more bacteria selected from the genus Lactobacillus. More specifically, the invention relates to the utilization of one or more species or strains of Lactobacillus producing bacteria for the control of urinary tract bacteria and pathogens, including antibiotic-resistant urinary tract pathogens, and their associated diseases by both a reduction in the rate of colonization of the infection and pathogens. The method for treatment and relief from symptoms includes administration via a rectal suppository with a safe and effective amount of the composition. The delivery mode for administering the probiotic is via a rectal suppository. The delivery through the rectum provides an optimum method of transmission of the treatment.

A method for treating human immuno-deficiency virus infection (HIV-1), comprising administering a therapeutically effective amount of a mammalian liver extract characterized by being heat stable, insoluble in acetone, and soluble in water. A rectal suppository colloidal dispersion delivery system for use in the treatment of HIV-1 infection further comprises an emulsion of resolubilized, concentrated mammalian liver extract.

The invention relates to a preparation of anemoside B4 for rectal mucosal administration, comprising anemoside B4 and a pharmaceutically acceptable matrix; the preparation herein is selected from oneor two of rectal gel and rectal suppository. The invention also specifically provides rectal gel of anemoside B4, rectal suppository of anemoside B4, and their preparation methods. The preparation ofanemoside B4 for rectal mucosal administration provided herein requires less dosage than oral administration and has better effect under the same the dosage.

The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

The present invention relates a composition comprising Diclofenac and salts thereof wherein Diclofenac or its salts are present in an amount of 25-200 mg. The composition is suitable for the parenteral administration through intramuscular, intravenous route; also for oral, dermal, subcutaneous, cutaneous, nasal, ocular drops, as rectal suppository, vaginal pessaries, intra-articular, and otic delivery. The invention also provides compositions comprising a combination of Diclofenac and other drugs. The invention further provides a method for preparing said composition.

The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m²/g to about 2.8 m²/g (e.g., from about 0.1 m²/g to about 1.3 m²/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

A mesalamine rectal suppository having improved comfort of use and better retention in lower rectum for a long period of time is provided. The suppository contains a suppository base, at least one surfactant and at least one mucoadhesive agent. A method for manufacturing the suppository and methods for treating ulcerative colitis, such as active ulcerative proctitis, using such suppository is also provided.

A rectal mucosal administration preparation of Pulsatilla chinensis (Bge.) Regel saponin B4 contains Pulsatilla chinensis (Bge.) Regel saponin B4 and a pharmaceutically acceptable substrate. The drug preparation is a rectal gel or a rectal suppository. Compared with oral administration, the rectal mucosal administration preparation of Pulsatilla chinensis (Bge.) Regel saponin B4 has a lower effective dose, and has a better medicinal effect at the same dose.

The present invention discloses a rectal suppository. It is characterized by that in the course of its production the tourmaline, wheat-ball stone and magnet can be added, and the long-term application of said suppository is beneficial to prostate.

The current invention provides formulations for transdermal delivery of promethazine which achieve delivery of the drug with consistent plasma levels. The topical formulations of the invention are superior to both rectal suppositories and oral dosage forms in that variable blood levels, first-pass metabolism, unpredictable peaks in blood levels, and variable bioavailability are minimized. Formulations of the invention provide antiemetic and antipruritic relief to patients in need of treatment while minimizing side effects and adverse reactions known to occur with other routes of administration and other formulations.

The present invention discloses a rectal cancer photodynamic therapy mini-type LED illumination source based on wireless power supply. The source comprises bullet-shaped housing, the housing is internally provided a voltage regulator module and a LED light source with the wavelength range of 630-650nm, the housing is internally provided with a LC resonance matching receiving coil and a first rectification filter circuit, the LC resonance matching receiving coil is 20*5*2mm, and the inductance value is 60[Mu]H; the mini-type LED illumination source also comprises an electric power emission unit consisting of a current generation current and a LC resonance matching sending coil; and the current generation circuit is configured to generate alternating current to allow the LC resonance matching sending coil to generate resonance. The Rectal cancer photodynamic therapy mini-type LED illumination source based on the wireless power supply can obtain electric energy at any moment so as to solve the power supply problem in the rectal suppository therapy and enhance the reliability of the rectal suppository. The contradictions of the mini-type implantable medical device power supply and the small size, and the attention of medical staff to the rectal suppository electric quantity is saved, and a condition is created for the product clinical expansion.

A rectal suppository comprising mesalamine and a local anaesthetic agent is provided. The suppository contains a suppository base, at least one surfactant and at least one mucoadhesive agent. A method for manufacturing the suppository and methods for treating ulcerative colitis, such as active ulcerative proctitis, using such suppository is also provided.

The use of malachite green in the form of a tetramethyldiamino-triphenyl-carbinol anhydro-oxalate [(C₂₃H₂₅N₂)—(C₂HO₄)]₂—C₂H₂O₄ of the following structural formula as a drug for treating malignant neoplasms administered in a single doze of 1 to 2 g. Malachite green can be used when dissolved in an aqueous solution or in a physiological salt solution or in spirit. In different cases, the malachite green solution is perorally administered before and after a meal or is injected per rectum, or a 1% malachite green solution is intravenously introduced, or the malachite green is applied as a rectal suppository component or as a component of 1-5% ointment. The medicinal agent exhibits an extended range of therapeutic actions with respect to different oncological diseases, is freely available, not expensive, non-toxic, does not generate side effects when used in pharmaceutically acceptable doses, and makes it possible to reduce a treating time and to increase the efficiency of treatment.

The invention belongs to the field of pharmaceutical preparations and particularly relates to a periplaneta americana rectum drug preparation. The periplaneta americana rectum drug preparation is a rectum suppository taking various forms of periplaneta americana extracts as active ingredients. The periplaneta americana suppository provided by the invention has the effect of prolonging the drug release and action time or quickly releasing to take effects, can be used for treating ulcerative colitis-related diseases and indications, significantly relieves intestinal ulcer and inflammatory reaction and overcomes the defects of worse oral administration effect and slow effect, the drug action efficiency is improved, a better treatment mode is provided for clinical patients, and clinical medication forms of the periplaneta americana preparation are enriched.

The invention discloses an application of andrographolide in preparation of medicines for treating acute kidney injury, and a preparation method of an andrographolide rectal suppository for treating the acute kidney injury. The method comprises the steps that 220-240 parts of semi-synthetic fatty glyceride is heated into a molten state, 5-15 parts of andrographolide powder is added and uniformly stirred, the mixture is cooled to room temperature and injecting a rectal suppository mould, and demoulding is carried out after the suppository is solidified. The effective components of the preparedandrographolide rectal suppository are easier to absorb, release is fast, and the efficacy time is long.

The invention discloses a gynecological pelvic inflammatory disease rectal suppository and a preparation method thereof. The suppository includes: 1.0-5.0g of span-40, 2.0-5.0g of sodium stearate, 16.0-27.0g of glycerol, 0.1-0.4g of tween-80, 0.02-0.10g of benzoic acid, 7.0-16.0g of bee wax, 0.1-0.7g of berberine, 0.8-3.0 ml of lithospermum soaked oil, 0.8-3.9g of chrysanthemum indicum extracted liquid and 1.0-4.0g of coconut oil. The gynecological pelvic inflammatory disease rectal suppository is light yellow in color, is moderate in hardness, is uniform in texture and is free of irritation. A weight difference and a melting time are in conformity with a requirement. The berberine, the lithospermum soaked oil and the chrysanthemum indicum extracted liquid and the like ingredients are good in antisepsis and anti-inflammation effect. The suppository is an effective drug for treating gynecological pelvic inflammatory disease and deserves to be further popularized and applicated.

The invention relates to a compound preparation used for preventing and treating animal viral diseases. The compound preparation mainly comprises a polyinosinic acid-polycytidylic acid polymer and appropriate auxiliary materials. Polyinosinic-polytidylin acid has high-efficiency interferon induction and immune adjustment effects. A conventional polyinosinic-polytidylin acid preparation is widely used for preventing and treating human and animal viral diseases; and the preparation formulation is an injection, an eye drop and the like. The injection has the disadvantages of great stress, inconvenient use and the like. Therefore, in order to bring convenience to animal medication, the preparation is prepared into a rectal suppository which is suitable to be used for animals by special process treatment, and simultaneously provides a feasible way for industrial large-scale production and is suitable for popularization and application.